FDA Logo, hands holding pills

Viberzi (eluxadoline) Safety Podcast

FDA review shows increased risk of serious pancreatitis in patients without a gallbladder

  • Prescribed to treat irritable bowel syndrome with diarrhea (IBS-D)
  • Patients, without a gallbladder, have increased risk of developing serious pancreatitis that could result in hospitalization or death
  • Pancreatitis caused by spasm of certain digestive system muscle in the small intestine
  • FDA working with manufacturer, Allergan, to address safety concerns

LISTEN & LEARN


 


Leave a Reply


Fill in your details below or click an icon to log in:

WordPress.com Logo



You are commenting using your WordPress.com account.
Log Out / 
Change )

Google photo



You are commenting using your Google account.
Log Out / 
Change )

Twitter picture



You are commenting using your Twitter account.
Log Out / 
Change )

Facebook photo



You are commenting using your Facebook account.
Log Out / 
Change )

Connecting to %s